Navigation Links
SCIENCE CHINA Life Sciences English Edition Publishes Domestic Type 2 Diabetes Research Findings
Date:4/12/2017

China has the highest number of diabetes sufferers in the world. There are some 113 million[1] adult patients with type 2 diabetes in China, making up nearly 1/4 of the total globally; nearly 2/3 are unable to keep their blood glucose within safe levels. Type 2 diabetes is a chronic progressive disease - over time, relying solely on a single drug to lower blood glucose is rarely effective.

"Combination therapy is required to keep glucose levels under control in many patients with diabetes, but the lack of high quality evidence-based medical science to support the therapy choices of Chinese doctors mean that in clinical practice, many physicians are unable to start prescribing combination therapies in a timely manner, resulting in patients suffering excessively high blood sugar levels over a long period. This is 'clinical inertia'. The issue of which combination therapies are best suited to Chinese diabetes sufferers, and how to overcome clinical inertia and seize the best opportunity for adding on therapies for better blood sugar level control have been something that we have continued to explore and thought  over in clinical practice," said Professor Weng. "At the moment, standard guidelines advocate the treatment protocol of 'single drug-dual therapy-triple therapy-combination injection therapy'; but in clinical practice, physicians are often - because of a lack of clinical evidence and treatment consensus - unwilling to try the triple combination oral therapy for lowering blood glucose, which results in what is termed 'clinical inertia'. Currently, the all new diabetes oral drug DPP-4 inhibitor has become an important option as a second-line drug for the treatment of type 2 diabetes, and has also been included in the 2017 National Reimbursement Drug List (NRDL). But when therapies based on a combination of Metformin and Sitagliptin fail to keep blood glucose levels under control in patients, what about the next step - a triple combination oral therapy? The STRATEGY study bridges this gap in clinical evidence."

STRATEGY creates many firsts in China

STRATEGY started officially in August 2012. The study is supported by the Chinese Medical Association(CMA) and Sun Yat-Sen University, with the Third Affiliated Hospital of Sun Yat-Sen University at the lead and MSD China as sponsor. It has created a number of records in China:

  • Researches from 237 clinical research centers across China participated in the study
  • The study covered 5,535 patients with type 2 diabetes from 25 provinces and municipalities, of different geographical regions, age, and gender

Professor Jianping Weng stressed: "There were seven experts leading STRATEGY across different regions nation-wide, a consultative committee with nearly 20 diabetes experts and many other international experts provided guidance and supervision to ensure that the study would be fair, objective, and scientific. The entire research process was conducted in adherence to the treatment recommended in the China Guideline for Type 2 Diabetes, and explored the most suitable combination therapy solution for patients with diabetes in China through a sequential research design. The time span, scale, and coverage of this randomized controlled clinical study produce findings that represent a significant contribution to the accumulation of local data for diabetes research in China, and also provide high quality medical evidence for raising the standards of diabetes care in China."

Key Findings of the STRATEGY Study

STRATEGY is a study completely localized for China, designed specially for patients with type 2 diabetes in China, and addresses a practical clinical problem. The design of the study was based on the current treatment recommendations for type 2 diabetes in China, and proves that the dual-therapy treatment with Metformin and the DPP-4 inhibitor Sitagliptin - as well as the timely and early addition of a commonly used anti-diabetic drug (Glimepiride, Gliclazide, Repaglinide, Acarbose) to form a triple combination therapy, are safe and effective in treating diabetes sufferers in China.

The results showed that in patients that cannot be effectively treated with the single drug Metformin, the addition of the DPP-4 inhibitor Sitagliptin for 16 weeks significantly reduced glycated hemoglobin[2] (-0.85%, base level 8.03%), bringing down glucose levels to the target range in 44.3% of cases. In patients where dual therapy is ineffective in controlling glucose levels, the addition of a third anti-diabetic drug commonly used in China (Glimepiride, Gliclazide, Repaglinide, Acarbose) in the 20th week was shown to further reduce glycated hemoglobin (-0.59%, randomized level of 7.72% before). In the duration of the STRATEGY study, blood glucose levels were brought down to the target range in 62.3% of patients, with good tolerance. The early and timely introduction of dual and triple therapies is effective in controlling blood glucose, and provides a feasible solution for overcoming "clinical inertia".

Letting the Study Findings take root and blossom in China

Professor Zengyi Chang, Deputy Editor-in-chief of SCIENCE CHINA Life Sciences stressed, "The majority of researchers in science and technology should author their papers in their motherland, and use the fruit of their research to advance the great cause of modernization, as National Scientific Meeting has request. It is gladdening to see groundbreaking scientific research - as represented by the STRATEGY study, increasingly being published in Chinese scientific journals, displaying China's scientific spirit as well as boosting the influence of local scientific journals.

Prof. Chang said, "Since the start of SCIENCE CHINA Life Sciences, it has always upheld its motto of 'Progressing with Science in China', publishing a large number of important papers by Chinese scientists, and bearing witness to the growth, development, and progress of science in New China, making a positive contribution to enriching academic exchange both at home and abroad, and boosting development in science and technology. Moving forward, we hope to see more excellent research papers being published in Chinese scientific journals. As the status of academic research in China continues to rise internationally, and research studies in China gain momentum and better standing, publishing outstanding research papers authored in China in Chinese journals will become the order of the day!"

STRATEGY is also a model for four-way collaboration between medical associations, research institutions, hospitals, and corporations - MSD China, together with the Chinese Medical Association and the Third Affiliated Hospital of Sun Yat-Sen University provided an excellent platform for learning and exchange for all the institutions involved in the STRATEGY study. MSD China said the company will continue take the initiative to contribute to Healthy China 2030, advancing diabetes prevention and control to help more patients get better treatment and live healthier lives.

[1] Jianping, Weng. China Diabetic Treatment Strategy Preliminary Target [J]. Chinese Journal of Medical Information, 2014, 29:10-10. DOI: 10.3760/j.issn.1000-8039.2014.16.006.

[2] Glycated hemoglobin, HbA1c for short, is hemoglobin to which glucose is bound. It is commonly measured to show the average plasma glucose concentration over a period of 8~12 week period in patients.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/science-china-life-sciences-english-edition-publishes-domestic-type-2-diabetes-research-findings-300438644.html


'/>"/>
SOURCE SCIENCE CHINA
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
2. Strand Life Sciences Creates Another Global Bioinformatics Landmark With Strand Ramanujan
3. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
4. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
5. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
6. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
7. Twist Bioscience Raises $33 Million
8. Dr. Jane Chin, President & Founder of the Medical Science Liaison (MSL) Institute appointed by the Accreditation Council for Medical Affairs (ACMA) as Chair of Scientific Advisory Board Committee
9. Medical Appliances Stocks Under Scanner -- Neovasc, Hologic, Edwards Lifesciences, and Sunshine Heart
10. Medical Instruments Stocks Under Scanner -- Waters, Integra LifeSciences, Insulet, and Cooper
11. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology:
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
Breaking Medicine News(10 mins):